science
Conflict-of-interest questions after a decade of HCA

Camille MacMillin/STAT
Within the International Human Cell Atlas Consortium, Alexandra-Chloé Villani is known as a pioneer in using single-cell technologies to understand the immune system and how it responds to certain drugs. She’s an organizer for a major meeting that the group will hold this week in Boston, and she’s widely expected to be one of the people taking over a leadership role at the end of the year. What’s less known is that her husband is a senior executive at 10x Genomics, a company that makes critical technology for the consortium’s work and serves as the meeting’s top corporate sponsor.
In this rapidly moving field of biology, it’s not unusual for close ties between academia and industry to exist. Still, STAT’s Megan Molteni interviewed scientists involved with the HCA who said they were unaware of the relationship, and that it’s something that should be disclosed to the community. Read more on the ties that underlie the complicated, expensive work HCA scientists contribute to.
habits
How supplement use changed over decades
The prevalence of supplement use among American adults has increased markedly since the turn of the millennium: In 1999, 51% of adults took supplements, compared to 60% in 2023, according to a new study in JAMA Network Open.
Researchers analyzed annual data from a nationally representative CDC health survey that included participant interviews on supplement use. They found that the use of these products really took off after 2009-10, particularly among older adults. Immune and anti-inflammatory products such as zinc, elderberry, and ashwagandha saw usage increases long term and over the Covid pandemic. Vitamin use increased, but multivitamin-multimineral use actually decreased, which the researchers propose is connected to a growing preference for personalized medicine.
first opinion
How an Alzheimer’s expert missed it in her own father
The biology of Alzheimer’s disease begins 15 to 20 years before a family starts noticing something is off. Neurologist Elizabeth Bevins knows this, but still, she missed the quiet, early signs of disease in her father. “Not because I lacked training,” she writes in a new First Opinion essay. “But because I was trained to wait for unmistakable decline before acting.”
That, she argues, is the wrong lesson. Bevins sees the need for fundamental shift in the way brain health is treated: more early risk identification, surveillance over time, and intervention before irreversible damage. Read more on the case for acting earlier, as well as which risks might accompany such a strategy.